Jaguar Health (JAGX) vs Moleculin Biotech (MBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jaguar Health is the larger company by market cap ($8.8 million vs $8.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAGX | MBRX |
|---|---|---|
| Share price | $4.53 | $0.424 |
| Market cap | $8.81M | $8.64M |
| 1-day change | -9.40% | -3.39% |
| P/E ratio (TTM) | — | 0.05 |
| EPS (TTM) | $-4,012.65 | $8.98 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1,267.88 | $15.75 |
| 52-week low | $2.35 | $0.161 |
| Distance from 52-week high | -99.64% | -97.31% |
| Average volume | 2.00M | 1.28M |
| Shares outstanding | 1.95M | 20.39M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
JAGX vs MBRX FAQ
Which is bigger, Jaguar Health or Moleculin Biotech?
Jaguar Health (JAGX) is larger, with a market capitalization of $8.81M compared with $8.64M for Moleculin Biotech (MBRX).
Are Jaguar Health and Moleculin Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.